In the subgroup of neoadjuvantly treated GC patients, we identified only a trend toward an association of a higher NOTCH1 and NOTCH2 expression in the pretherapeutic biopsies and worse tumor regression after chemotherapy. This evidence concerns the gene NOTCH2 and gastric cancer.